Innhold levert av CancerCare. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av CancerCare eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.

People love us!

User reviews

"Elsker offline-funksjonen"
"Dette er "den" måten å håndtere podcastabonnement på. Det er også en bra måte å utforske nye podcaster."

Diffuse Large B-Cell Lymphoma (DLBCL): New Treatment Approaches

56:47
 
Del
 

Fetch error

Hmmm there seems to be a problem fetching this series right now. Last successful fetch was on August 31, 2023 19:05 (3M ago)

What now? This series will be checked again in the next day. If you believe it should be working, please verify the publisher's feed link below is valid and includes actual episode links. You can contact support to request the feed be immediately fetched.

Manage episode 371502496 series 1475911
Innhold levert av CancerCare. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av CancerCare eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
- Overview of Diffuse Large B-Cell Lymphoma (DLBCL), in the Context of COVID, Omicron & Seasonal Flu - Staging, Grading & Current Standard of Care - Treatment Options for Relapsed Refractory DLBCL - Bispecific Antibodies for Relapsed Refractory DLBCL - Understanding How Bispecific Antibodies Work in the Treatment of Relapsed Refractory DLBCL - New and Emerging Treatment Approaches - The Role of Clinical Trials - How Research Contributes to Treatment Choices - Tips to Manage Side Effects, Symptoms, Discomfort & Pain - Talking with Your Health Care Team about Quality-of-Life Concerns - Guidelines to Prepare for Telehealth/Telemedicine Appointments, including Technology, Prepared List of Questions & Discussion of OpenNotes - Questions for Our Panel of Experts
  continue reading

153 episoder

iconDel
 

Fetch error

Hmmm there seems to be a problem fetching this series right now. Last successful fetch was on August 31, 2023 19:05 (3M ago)

What now? This series will be checked again in the next day. If you believe it should be working, please verify the publisher's feed link below is valid and includes actual episode links. You can contact support to request the feed be immediately fetched.

Manage episode 371502496 series 1475911
Innhold levert av CancerCare. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av CancerCare eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
- Overview of Diffuse Large B-Cell Lymphoma (DLBCL), in the Context of COVID, Omicron & Seasonal Flu - Staging, Grading & Current Standard of Care - Treatment Options for Relapsed Refractory DLBCL - Bispecific Antibodies for Relapsed Refractory DLBCL - Understanding How Bispecific Antibodies Work in the Treatment of Relapsed Refractory DLBCL - New and Emerging Treatment Approaches - The Role of Clinical Trials - How Research Contributes to Treatment Choices - Tips to Manage Side Effects, Symptoms, Discomfort & Pain - Talking with Your Health Care Team about Quality-of-Life Concerns - Guidelines to Prepare for Telehealth/Telemedicine Appointments, including Technology, Prepared List of Questions & Discussion of OpenNotes - Questions for Our Panel of Experts
  continue reading

153 episoder

Alle episoder

×
 
Loading …

Velkommen til Player FM!

Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.

 

Player FM - Podcast-app
Gå frakoblet med Player FM -appen!

Hurtigreferanseguide

Copyright 2023 | Sitemap | Personvern | Vilkår for bruk | | opphavsrett